Compounds used to treat and prevent COVID-19
By developing hexahydroxystilbene derivative compounds, the problem of the ineffectiveness of existing anti-COVID-19 drugs has been solved, achieving significant inhibition of SARS-CoV-2 and effective prevention and treatment of COVID-19. The non-invasive administration route provides a rapid and safe treatment option.
Patent Information
- Application Number
- CN202280024304.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2021-03-25
- Filing Date
- 2022-03-14
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2042-03-14
AI Technical Summary
Existing anti-COVID-19 drugs have not shown effective inhibitory activity against SARS-CoV-2, and traditional treatments are time-consuming and invasive. There is a need for rapid and safe alternatives to prevent viral infection and reduce severe symptoms.
A polyphenolic compound containing a specific structure, especially a hexahydroxystilbene derivative, was developed to inhibit SARS-CoV-2 entry into cells and prevent viral replication via oral, sublingual, or nasal routes, utilizing its broad-spectrum antiviral activity and good tolerability.
These compounds significantly enhance the inhibitory effect against SARS-CoV-2, offering the potential for effective prevention and treatment of COVID-19, and are readily available, safe, and suitable for non-invasive administration.
Smart Images

Figure CN117222406B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the treatment and prevention of COVID-19. Background Technology
[0002] In December 2019, a novel coronavirus (SARS-CoV-2) began to trigger a pandemic that will continue until an effective and safe vaccine or a drug treatment for the cause of the disease can help prevent severe and fatal cases. To date, millions of people worldwide are waiting for an effective treatment for the disease, and that number continues to rise.
[0003] To date, no specific drug has been found to control this disease. Developing new treatments is often very time-consuming; therefore, using repurposing broad-spectrum antiviral drugs is generally considered an effective strategy for an immediate response. Consequently, the effects of known antiviral compounds have been extensively studied.
[0004] In particular, “repurposing” naturally occurring or previously developed synthetic antiviral compounds with broad-spectrum biochemical mechanisms against COVID-19 is seen as a promising strategy to combat the pandemic.
[0005] Substances such as griffithin, nafamostat (targeting cell entry), disulfiram, lopinavir / ritonavir, danoprevir, nelfinavir (targeting SARS-CoV-2 protease), favipiravir, ribavirin, penciclovir, remdesivir, and galixivir (targeting RNA-dependent RNA polymerase (RdRp)) have been discussed as promising candidates, but have not yet provided specific and effective treatment for SARS-CoV-2 in patients infected with COVID-19 (Ghanbari et al., Fut. Microbiol. 15 (2020), 1747-1758; Harrison, Nat. Biotechnol. 38 (2020), 379-381).
[0006] Phenolic compounds are homogeneously dispersed phytochemicals found abundantly in any tissue of most plant families worldwide, particularly in fruits and vegetables, which are part of the plant. Based on their chemical structure, phenolic compounds are classified into phenolic acids, flavonoids, tannins, coumarins, lignans, quinones, stilbenes, and curcuminoids. Phenolic compounds are synthesized via the shikimic acid pathway in plants, as these secondary metabolites are often involved in plant adaptation to environmental stress conditions. Phenolic and flavonoid compounds are secondary metabolites of plants, possessing an aromatic ring with at least one hydroxyl group. Among the diverse natural therapeutic agents, flavonoids and phenolic compounds are considered the most promising anti-SARS-CoV-2 active compounds due to their excellent pharmacokinetic properties.
[0007] Phenolic compounds have been reported to possess a variety of biological activities, such as antioxidant, anticancer, anti-inflammatory, antibacterial, cardioprotective, and immune system-boosting activities. Multiple studies have shown that phenolic and flavonoid compounds from medicinal plants can improve human health and enhance immunity. Natural polyphenolic compounds are primarily derived from plants. These phenolic and flavonoid compounds exhibit antiviral activity against various viruses, such as rhinovirus, hepatitis C virus, HIV, yellow fever, herpes simplex virus, and influenza virus. Today, pharmacology companies are leveraging bioinformatics tools and applications to produce potential drug molecules in a short time.
[0008] Through computer-based prediction and biochemical in vitro binding assays of SARS-CoV-2 components, many natural compounds (previously shown to inhibit other pathogens, such as polyphenols) have been suggested for the treatment of COVID-19, also based on computer screening (e.g., Rathinavel et al., Bioint. Res. Appl. Chem. 11 (2021), 10161-10173; Mhatre et al., Phytomed. (2020), 153286; Chojnacka et al., J. Funct. Food 73 (2020), 104146; Ghosh et al., J. Biom. St. Dyn. (2020), 1-13-doi.org-10.1080-07391102.2020; Islam et al., Phytother. Res. 3 (2020), 2471-2492; WO 2020 / 037095A1). The advantage of such compounds is that they are “generally recognized as safe” (“GRAS”; e.g., Sections 201(s) and 409 of the U.S. Federal Food, Drug, and Cosmetic Act), and therefore can be administered without preclinical studies (and also as a food supplement), and can be used immediately to treat COVID-19 patients and prevent them from developing severe illness.
[0009] Wahedi et al. (J. Biomol. Struct. Dyn. 39 (2021): 3225-3234) suggested resveratrol and, as a representative, 3',4',2,4-tetrahydroxy(-trans-)stilbene as candidate drugs against COVID-19. Zhang et al. (Cell Discovery 6 (2020), 80) reported that heparan sulfate can assist SARS-CoV-2 in entering cells and can be targeted in vitro by approved drugs, with mitoxantrone (as a potent heparan sulfate inhibitor), sunitinib, and BNTX as potential candidates for this approach. Further reports indicate that picaridin binds to heparin. CN 111 228 343 A appears to disclose an extract containing picaridin for the treatment of "2019-nCoV" infection. Han et al. (J. Med. Virol. 87(2015): 2054-2060) reported the HIV inhibitory activity of 3,3', 4,4', 5,5'-hexahydroxy-trans-stilbene.
[0010] However, these substances have not yet been shown to have suitable antiviral activity against SARS-CoV-2, so as to provide effective treatment or prevention options for patients infected with SARS-CoV-2. Summary of the Invention
[0011] Therefore, one object of the present invention is to provide practical and effective alternatives for the prevention or treatment of COVID-19. These alternatives should be effective in preventing or inhibiting SARS-CoV-2 from becoming pathogenic to human patients. Thus, the substances should at least partially inhibit SARS-CoV-2 and / or prevent or inhibit its entry into human cells, thereby providing significant benefits to patients by reducing the risk of contracting COVID-19 or mitigating the severity of the effects of COVID-19. Another object is that these substances are readily available, well-tolerated, and can be successfully applied to humans without invasive methods, preferably via inhalation, aerosol delivery, etc.
[0012] Therefore, the present invention provides a compound of formula I.
[0013]
[0014] Wherein R1 to R6 are the same or different and are H, OH- or OR7, wherein R7 is a C1 to C3 alkyl or C1 to C4 acyl, provided that at least four, preferably at least five, and especially at least six of R1 to R6 are not H, the compound is used to treat and prevent COVID-19 in human subjects, particularly to inhibit SARS-CoV-2.
[0015] The compounds according to the invention have been identified during the course of the invention as exhibiting practical and effective inhibitory activity against SARS-CoV-2. Therefore, the compounds according to the invention can effectively prevent or inhibit SARS-CoV-2 from causing disease in human patients. Accordingly, the compounds according to the invention are capable of at least partially inhibiting SARS-CoV-2 and / or preventing or inhibiting SARS-CoV-2 from entering human cells, thereby providing significant benefits to patients by reducing the risk of contracting COVID-19 or reducing the risk of severe impact from COVID-19. The compounds of the invention are readily available, well-tolerated, and can be successfully applied to humans without the need for invasive methods. Furthermore, the compounds of the invention are considered "GRAS," meaning they are "generally considered safe" (pursuant to Sections 201(s) and 409 of the U.S. Federal Food, Drug, and Cosmetic Act).
[0016] Preferably, the compounds used according to the present invention are selected from 3,3',5,5'-tetramethoxystilbene, 3,4,4',5-tetramethoxystilbene, 3,3',4,5'-tetramethoxystilbene, 3,3',4,5,5'-pentamethoxystilbene, 3,3',5,5'-tetrahydroxystilbene, 3,4,4',5-tetrahydroxystilbene, 3,3',4,5'-tetrahydroxystilbene, 3,3',4,4',5-pentahydroxystilbene, 3,3',4,5'-pentahydroxystilbene, 3,4,4',5,5'-pentahydroxystilbene, 3,3',4,4',5,5'-pentahydroxystilbene, 3,3',4,4',5,5'-pentahydroxystilbene, and 3,3',4,4',5,5'-hexahydroxystilbene, preferably 3,3',4,5,5'-pentamethoxystilbene, 3,3',4,4',5-pentahydroxystilbene, and 3,3',4',5'-hexahydroxystilbene. ,5,5'-pentahydroxystilbene, 3,4,4',5,5'-pentahydroxystilbene, 3,3',4',5,5'-pentahydroxystilbene, 3,3',4,4',5,5'-hexahydroxystilbene, especially 3,3',4,4',5,5'-hexahydroxystilbene.
[0017] Surprisingly, the compounds of the present invention exhibit significantly higher activity in inhibiting SARS-CoV-2 than similar polyphenolic substances that are thought to have antiviral activity. Although (-)-epigallocatechin gallate or (-)-gallocatechin gallate also shows more significant SARS-CoV-2 inhibitory activity than other polyphenols, particularly other compounds from green and black tea, the compounds of the present invention show significantly enhanced inhibitory activity compared to these substances.
[0018] The compounds according to the invention preferably inhibit SARS-CoV-2 replication and / or have a cytopathic effect for preventing active viral replication of SARS-CoV-2 and / or prevent infection with airborne SARS-CoV-2 virus.
[0019] In the course of this invention, the in vitro antiviral effects of nine polyphenolic plant components and one synthetic polyphenolic compound, 3,3',4,4',5,5'-hexahydroxytrans-stilbene (synthesized as an analogue of resveratrol, a wine component), were tested. The ability of nine natural compounds—gallic acid, (-)-catechin, (-)-catechin gallate, (-)-epigallocatechin gallate, (-)-epicatechin, (-)-epigallocatechin, (-)-gallocatechin gallate, ellagic acid (which has been suggested in the prior art as a potential antiviral compound), and hexahydroxytrans-stilbene (as a representative example of a synthetic resveratrol (trans-3,5,4'-trihydroxystilbene) analogue)—to inhibit viral replication in vitro was investigated.
[0020] The stilbene derivatives according to the invention have been previously disclosed, for example, see WO 02 / 50007 A2, WO 02 / 057219 A1, WO 2005 / 016860 A1 and WO 2007 / 002973 A2.
[0021] These (poly)hydroxyphenols exhibit stronger anticancer and anti-inflammatory effects than resveratrol due to the increased number of para-hydroxyl groups in polyhydroxystilbene. Hexahydroxystilbene shows the most potent anti-inflammatory and anticancer activity in vitro, demonstrating anticancer effects in animal studies and showing inhibition of HIV infection in the very early stages in vitro. These substances have also been disclosed as regulators of T cells, neutrophils, macrophages, and corresponding cytokines.
[0022] In CN 1736986 A, stilbene derivatives are proposed as antiviral substances against SARS-CoV-1. The disclosed compounds with antiviral activity are those containing a pyridine group and those substituted with 2,2'-OH or CH3O-, as well as those substituted with 3,3'-methyl-butenyl. Furthermore, the properties of these compounds with genuine anti-SARS activity are not disclosed.
[0023] All the compounds tested were excellent free radical scavengers, exhibiting broad biochemical activity, such as inhibiting key enzymes in DNA synthesis or inflammation. Furthermore, some of them were shown to inhibit various viral infections by non-specifically inhibiting viral entry or replication. These compounds were chosen because of their chemical structure and availability in natural sources such as tea or fruit.
[0024] The inhibitory effects of all compounds on viral infection were studied using an in vitro cell culture model.
[0025] The receptor through which SARS-CoV-2 docks with cells is the ACE2 receptor. Binding studies were conducted on three compounds that showed the most effective antiviral effects.
[0026] Compared with other suggestions in the prior art describing several polyphenolic substances from green and black tea as having potential anti-SARS-CoV-2 properties, the present invention demonstrates that polyphenolic substances vary greatly in their anti-SARS-CoV-2 effects, and only a few of these substances are effective.
[0027] These experiments conducted during the course of the present invention demonstrate that the synthetic resveratrol analogues according to the present invention, preferably in their tetrahydroxy, pentahydroxy, and hexahydroxy forms, especially hexahydroxystilbene, exhibit significantly superior inhibitory activity against SARS-CoV-2 compared to other natural polyphenolic compounds, and even a few natural polyphenolic compounds that have been shown to have real-world antiviral activity against SARS-CoV-2 (contrary to optimistic predictions based on analogies with other viruses or computer predictions).
[0028] The compounds of this invention are generally referred to as pharmaceutical substances. Therefore, formulations known and proven effective for delivering these compounds to human subjects are also applicable to this invention. Routes of administration may include enteral or parenteral administration, such as oral, sublingual, intramuscular, subcutaneous, nasal, oral mucosa, skin, peritoneum, or rectal administration, preferably oral, sublingual, or nasal, particularly as inhalable and / or aerosol compositions. The compounds of this invention or pharmaceutical compositions comprising them may be administered in unit dosage forms. Dosage forms may be liquid or solid. For example, liquid dosage forms may be true solutions, colloids, microparticles, emulsions, or suspensions. Examples of dosage forms include tablets; caplets; capsules, such as hard gelatin capsules and soft elastic gelatin capsules; cachets; troches; lozenges; dispersants; suppositories; ointments; catalysts / poultices; pastes; powders; dressings; creams; plasters; solutions; patches; aerosols (e.g., nasal sprays or inhalers); sublingual films or tablets; lollipops; gels; and liquid dosage forms suitable for oral or mucosal administration to patients, including suspensions (e.g., aqueous or non-aqueous liquid suspensions, oil-in-water emulsions, or water-in-oil emulsions), solutions, and elixirs. The compounds of this invention can be formulated into conventional formulations, as well as sustained-release, controlled-release, targeted formulations, and various particulate delivery systems.
[0029] Therefore, this invention relates to the use of pharmaceutical formulations comprising the compounds of the present invention and pharmaceutically acceptable excipients. Pharmaceutically acceptable excipients can be any excipient known to be suitable for use with the compounds of the present invention, particularly carriers or diluents.
[0030] To prepare unit dosage forms, a wide variety of carriers known in the art can be used.
[0031] Examples of carriers or diluents include, for example, absorbents such as starch, dextrin, calcium sulfate, lactose, mannitol, sucrose, sodium chloride, glucose, urea, kaolin, microcrystalline cellulose, aluminum silicate, etc.; wetting agents and binders such as water, glycerin, polyethylene glycol, ethanol, propanol, starch syrup, dextrin, syrup, honey, glucose solution, gum arabic syrup, gelatin syrup, sodium carboxymethyl cellulose, shellac, methylcellulose, potassium phosphate, polyvinylpyrrolidone, etc.; disintegrants such as dry starch, alginate, agar powder, sodium bicarbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid ester, sodium dodecyl sulfate, methylcellulose, ethylcellulose, etc.; disintegration inhibitors such as sucrose, tristearate, cocoa butter, hydrogenated oil, etc.; absorption promoters such as quaternary ammonium salts, sodium dodecyl sulfate, etc.; lubricants such as talc, silica, corn starch, stearic acid, boric acid, liquid paraffin, polyethylene glycol, etc. Other carriers include polyacrylic acid resins, liposomes, water-soluble carriers such as PEG4000 and PEG6000, PVP, etc. Tablets can also be further formulated into sugar-coated tablets, film-coated tablets, enteric-coated tablets, or bilayer and multilayer tablets. For example, various carriers known in the art can be widely used to formulate the drug delivery unit into pills. Examples of carriers include diluents and absorbents such as glucose, lactose, starch, cocoa butter, hydrogenated vegetable oil, polyvinylpyrrolidone, kaolin, talc, etc.; binders such as gum arabic, astragalus gum, gelatin, ethanol, honey, liquid sugar, rice paste or batter, etc.; disintegrants such as agar powder, dry starch, alginate, sodium dodecyl sulfate, methylcellulose, ethylcellulose, etc. For example, to formulate the drug delivery unit into capsules, the compound of the present invention is mixed as the active ingredient with the various carriers described above, and the resulting mixture is placed in a hard gelatin capsule or a soft capsule. The active ingredients of the compounds of the present invention can also be formulated into microcapsules, suspended in an aqueous medium to form a suspension, or filled into hard capsules or formulated into injections, inhalers, or aerosols for administration. For example, the compounds of the present invention can be formulated into injection, inhaler, or aerosol formulations, such as solutions, suspensions, emulsions, or lyophilized powders, which can be aqueous or non-aqueous.
[0032] The pharmaceutical formulations of the present invention may contain one and / or more pharmacodynamically acceptable excipients, such as carriers, diluents, binders, lubricants, preservatives, surfactants, or dispersants. For example, diluents may be selected from water, ethanol, polyethylene glycol, 1,3-propanediol, ethoxylated isostearyl alcohol, polyoxyethylene isostearyl alcohol, polyoxyethylene sorbitol fatty acid esters, etc. Additionally, to prepare isotonic inhalation solutions / suspensions, aerosols, or injections, appropriate amounts of sodium chloride, glucose, or glycerol may be added to the injectable formulations. Furthermore, conventional solubilizers, buffers, pH adjusters, etc., may be added. These excipients are commonly used in this field. Additionally, if desired, colorants, preservatives, flavorings, sweeteners, or other materials may be added to the pharmaceutical formulations.
[0033] To achieve the therapeutic purpose and enhance the therapeutic effect, the medicament or pharmaceutical composition of the present invention can be administered by any known method of administration. The dosage of the extract or compound or pharmaceutical composition of the present invention depends on various factors, such as the nature and severity of the disease to be prevented or treated, the sex, age, weight, personality, and individual response of the patient or animal, the route of administration, the frequency of administration, and the therapeutic purpose; therefore, the therapeutic dosage of the present invention can vary widely. Generally, the dosage of the active pharmaceutical ingredient of the present invention is well known to those skilled in the art. The actual amount of the drug contained in the final formulation of the compound composition according to the present invention can be appropriately adjusted to meet the requirements of a therapeutically effective dosage; the dosage of the compound of the present invention can be achieved, preferably 0.1-20 mg / kg body weight.
[0034] The above dosage can be administered in a single dosage form or in several dosage forms, such as two, three or four, depending on the clinical experience of the attending physician and the administration regimen (including the use of other treatment methods).
[0035] According to a preferred embodiment, the polyphenolic compounds of the present invention are formulated for delivery to the upper respiratory system. Exemplary formulations include nasal formulations, bronchial formulations, oral formulations, and pulmonary formulations. However, the compounds according to the present invention can also be formulated for topical application, including liquids, gels, waxes, or pastes. The compositions of the present invention are particularly preferred as aerosols. Aerosols can be liquid or powdered aerosols. In some embodiments, the composition contains one or more pharmaceutically acceptable excipients, such as glycerin. The composition may contain 0.01%-20% w / v of the active ingredient of the present invention and 10% to 20% glycerin.
[0036] The pharmaceutical compositions and unit dosage forms disclosed herein typically also include one or more pharmaceutically acceptable excipients, particularly carriers or diluents. The advantages offered by the specific compounds disclosed herein, such as increased solubility and / or enhanced flowability, purity, or stability (e.g., hygroscopicity), may make them more suitable for drug formulation and / or administration to patients than existing technologies.
[0037] Suitable excipients are well known to those skilled in the art of pharmacy or pharmaceutics. Whether a particular excipient is suitable for inclusion in a pharmaceutical composition or dosage form depends on a number of factors well known in the art, including the manner in which the dosage form is administered to a patient. For example, oral dosage forms such as tablets or capsules may contain excipients unsuitable for parenteral dosage forms. The suitability of a particular excipient may also depend on the specific active ingredient in the dosage form. For example, the degradation of some active ingredients can be accelerated by some excipients (e.g., lactose) or by exposure to water. Active ingredients containing primary or secondary amines are particularly susceptible to this accelerated degradation.
[0038] Particularly preferred pharmaceutically acceptable excipients are antioxidants (reducing agents). Commonly used antioxidants in pharmaceutical compositions include citric acid and its salts (E330-E333), tartaric acid and its salts (E334-E337), phosphoric acid and its salts (E338-E343), ethylenediaminetetraacetic acid (EDTA) and its salts (EDTA disodium calcium, E385), vitamins C and E, etc.
[0039] This disclosure further covers pharmaceutical compositions and dosage forms comprising one or more compounds that reduce the rate of degradation of the active ingredient. Examples of such compounds are stabilizers, such as antioxidants (e.g., ascorbic acid), pH buffers, or salt buffers. Furthermore, the pharmaceutical compositions or dosage forms of this disclosure may contain one or more solubility modifiers, such as sodium chloride, sodium sulfate, sodium phosphate, potassium phosphate, or organic acids. One specific solubility modifier is tartaric acid.
[0040] Similar to the amount and type of excipients, the amount and specific type of the compound of the present invention in the dosage form can depend on factors such as the route of administration to the patient. Typical dosage forms of the compound of the present invention contain an amount of the active ingredient of the present invention from about 100 μg to about 10 g, preferably from about 1 mg to about 1 g, more preferably from 10 mg to 500 mg, and even more preferably from about 20 mg to about 300 mg. Preferred dosage forms contain an amount of the compound of the present invention from about 10 mg to about 1000 mg, preferably from about 25 mg to about 750 mg, more preferably from 50 mg to 500 mg, and even more preferably from about 30 mg to about 100 mg.
[0041] Preferably, the pharmaceutical composition may further include a carrier, such as a sugar alcohol, including but not limited to glycerol, mannitol, sorbitol, xylitol, and erythritol. In one specific embodiment, the sugar alcohol is glycerol.
[0042] Typical topical dosage forms include liquids, creams, lotions, ointments, gels, pastes, sprays, aerosols, solutions, emulsions, and other forms known to those skilled in the art. In a preferred embodiment, the compounds of the present invention are delivered to the oral cavity, nose, or bronchial tissue in a suitable topical dosage form.
[0043] For non-sprayable topical formulations, they are typically in viscous to semi-solid or solid form, containing a carrier or one or more excipients compatible with topical application and having a dynamic viscosity preferably greater than that of water. Suitable formulations include solutions, suspensions, emulsions, creams, ointments, powders, gels, waxes, pastes, liniments, salves, etc., which are sterilized or, if necessary, combined with excipients (e.g., preservatives, stabilizers, wetting agents, buffers, or salts) to affect various properties, such as osmotic pressure.
[0044] Nasal spray pharmaceutical products contain a therapeutic active ingredient dissolved or suspended in a solution or excipient mixture in a non-pressurized dispenser that delivers a metered dose of the spray containing the active ingredient. The dose can be metered by a spray pump or pre-metered during manufacturing. Nasal spray devices can be designed for single-dose administration or can spray up to hundreds of metered formulation sprays containing the drug substance. Nasal sprays are applied to the nasal cavity to produce local and / or systemic effects.
[0045] According to another preferred embodiment, the compounds of the present invention are provided in the form of inhalation solutions and suspensions of pharmaceutical products. Such products are typically water-based formulations containing a therapeutically active ingredient and may also contain additional excipients. Water-based oral inhalation solutions and suspensions must be sterile. Inhalation solutions and suspensions are intended to be delivered to the lungs via oral inhalation to produce local and / or systemic effects and are used with a specific nebulizer. Inhalation spray pharmaceutical products consist of a formulation and a container closure system. These formulations are typically water-based and must be sterile. Inhalation sprays are intended to be delivered to the lungs via oral inhalation to produce local and / or systemic effects. Other suitable local dosage forms include aerosol formulations in which the active ingredient (preferably in combination with a solid or liquid inert carrier) is packaged in a mixture with a pressurized volatile (e.g., a gaseous propellant such as Freon) or in a squeeze bottle. Examples of aerosol formulations include metered-dose inhalers, dry powder inhalers, and nebulizers. If necessary, moisturizers or humectants can also be added to the pharmaceutical composition and dosage form.
[0046] Pharmaceutical compositions according to the invention can also be advantageously provided in transdermal and mucosal dosage forms, such as eye drops, patches, sprays, aerosols, creams, lotions, suppositories, ointments, gels, solutions, emulsions, suspensions, or other forms known to those skilled in the art. Dosage forms suitable for treating oral mucosal tissues can be formulated as mouthwashes, oral gels, or buccal patches. Other transdermal dosage forms include reservoir-type or matrix-type patches that can be applied to the skin and worn for a specific period of time to allow the desired amount of active ingredient to penetrate. Suitable excipients (e.g., carriers and diluents) and other materials that can be used to provide transdermal and mucosal dosage forms are well known to those skilled in the pharmaceutical art and depend on the specific tissue or organ to which a given pharmaceutical composition or dosage form is to be applied. In view of this fact, typical excipients include water, acetone, ethanol, ethylene glycol, propylene glycol, 1,3-butanediol, isopropyl myristate, isopropyl palmitate, mineral oil, and mixtures thereof to form non-toxic and pharmaceutically acceptable dosage forms. Depending on the specific tissue to be treated, additional components may be used before, during, or after treatment with the compounds of this invention. For example, penetration enhancers may be used to help deliver the active ingredient to or across the tissue. Suitable penetration enhancers include acetone; various alcohols such as ethanol, oleyl alcohol, tetrahydrofuran, etc.; alkyl sulfoxides such as dimethyl sulfoxide; dimethylacetamide; dimethylformamide; polyethylene glycol; pyrrolidones, such as polyvinylpyrrolidone; Kollidon grades (Povidone, Polyvidone); urea; and various water-soluble or insoluble sugar esters, such as TWEEN 80 (polysorbate 80) and SPAN 60 (sorbitan monostearate).
[0047] The pH of the pharmaceutical composition or dosage form, or the tissue to which the pharmaceutical composition or dosage form is applied, can also be adjusted to improve the delivery of the active ingredient. Similarly, the polarity, ionic strength, or tonicity of the solvent carrier can be adjusted to improve delivery. Compounds such as stearates can also be added to the pharmaceutical composition or dosage form to advantageously alter the hydrophilicity or lipophilicity of the active ingredient, thereby improving delivery. In this regard, stearates can serve as lipid carriers in formulations, as emulsifiers or surfactants, and as delivery enhancers or penetration enhancers.
[0048] The compounds of this invention can also be formulated as extended or delayed-release formulations. Various extended and delayed-release formulations of active ingredients are known in the art, for example, through encapsulation.
[0049] The compounds of the present invention are present in the pharmaceutical composition at about 0.001% to about 50% w / v, typically about 0.01% to about 0.1% w / v, and more typically about 1% to about 20% w / v. In a preferred embodiment, the compounds of the present invention are present at about 0.01% to about 20% w / v. Then, pharmaceutically acceptable excipients and final other compounds or reagents present in the pharmaceutical composition are added to make 100%.
[0050] The compounds and compositions of the present invention can be used to treat one or more symptoms of SARS-CoV-2 virus infection. Preferably, the pharmaceutical compositions according to the invention are formulated for nasal or oral administration, such as drops, applicators, or sprays. One embodiment provides a composition according to the invention for prophylactic or therapeutic treatment of patients infected with or at risk of SARS-CoV-2 infection, particularly for the prevention of infection via airborne transmission.
[0051] According to another aspect, the present invention relates to the use of compounds according to the invention in the preparation of pharmaceutical formulations for the treatment and prevention of COVID-19 in human subjects, particularly for the inhibition of SARS-CoV-2. Preferably, the use is for inhibiting the replication of SARS-CoV-2 and / or for preventing the cytopathic effect of active viral replication of SARS-CoV-2 and / or for preventing SARS-CoV-2 infection via airborne transmission routes.
[0052] According to another aspect, the present invention relates to a method for treating and preventing COVID-19, particularly inhibiting SARS-CoV-2, in human subjects, wherein an effective amount of the compound or pharmaceutical preparation of the present invention is administered to a subject infected with or at risk of infection with SARS-CoV-2. This method is particularly suitable for inhibiting SARS-CoV-2 replication and / or preventing the cytopathic effects of active SARS-CoV-2 viral replication and / or preventing SARS-CoV-2 infection via airborne transmission in human subjects.
[0053] The present invention is further illustrated by the following embodiments and accompanying drawings, but is not limited thereto. Attached Figure Description
[0054] Figure 1 shows the tested compounds and their chemical structures; Compound I: gallic acid, Compound II: (-)-catechin, Compound III: (-)-catechin gallate, Compound IV: (-)-epigallocatechin gallate, Compound V: (-)-epicatechin, Compound VI: (-)-epicatechin gallate, Compound VII: (-)-epigallocatechin, Compound VIII: (-)-gallocatechin gallate, Compound IX: ellagic acid, and Compound X: hexahydroxy-trans-stilbene;
[0055] Figure 2 This demonstrates the effect of pre-insulation with the specified material on the TCID50 of SARS-CoV-2.
[0056] Figure 3 , 4 Figures 5 and 6 show the performance of compounds IV, VIII, and X in Vero cell culture assays with cells infected with SARS-CoV-2, where cells were infected after incubation and viral load was determined after incubation with different concentrations of the compounds for 48 hours. Viral infection was quantified in the supernatant using RT-PCR.
[0057] Figure 6 and 7 The supernatant was visualized by RT-PCR assay to quantify viral infection of compounds I to X (“s1” to “s10”) and remdesivir;
[0058] Figure 8 It shows two rounds of viral suppression;
[0059] Figure 9 The structures of resveratrol, piceatannol, and hexahydroxystilbene (compound X) are shown.
[0060] Figure 10 Displays viral copy numbers at different concentrations of compounds (dots: resveratrol, squares: piperazine, upward triangle: hexahydroxystilbene (compound X); downward triangle: positive control);
[0061] Figure 11The text shows the viral copy number at different concentrations of the compound, with RT-PCR in the supernatant used to quantify viral infection; the right column shows the positive controls: (A) resveratrol, (B) piperazine, (C) hexahydroxystilbene (compound X);
[0062] Figures 12 to 14 This study demonstrates the performance of hexahydroxystilbene (compound X), resveratrol, and paclitaxel in Vero cell culture assays of cells infected with SARS-CoV-2, where cells were infected after incubation and viral load was measured after incubation with different concentrations of the compounds for 48 hours. Example
[0063] In these examples, the inhibitory effects of compounds I to X on SARS-CoV-2 were investigated, including TCID50 of SARS-CoV-2 and Vero cell culture assays of cells infected with SARS-CoV-2.
[0064] Materials and methods
[0065] The cells were infected and incubated with all the compounds at different concentrations.
[0066] Median tissue culture infection dose (TCID50) determination
[0067] The night before the experiment, Vero cells were cultured at 1.5-2 x 10⁻⁶ m². 4 / wells were seeded at a density in 96-well plates in growth medium (DMEM containing 10% FCS, 100 μM non-essential amino acids, 1 mM sodium pyruvate, and penicillin / streptomycin). The next morning, the growth medium was removed, and 95% confluent Vero cells were pre-incubated for 45 minutes with DMSO or with 50 µM doses of Substances I, IV, VII, VIII, and X, and then infected with 100 µL of serially diluted SARS-CoV-2 virus stock solution. Pre-incubation and virus infection were performed in medium containing only 2% FCS instead of 10% FCS. After 5 to 7 days, cell viability was checked in all wells, and TCID was calculated with or without the specified substance using the method of Reed and Munch (Reed et al., Am. J. Epidemiol. 27 (1938), 493–497). 50 Dosage. Wells containing live cells and infected cells are identified using a reverse-light microscope, showing a clearly visible and intact Vero cell monolayer (live cells), or wells with a large number of CPE (cytopathic effect), characterized by a large number of dead cells and the absence of a monolayer (infected cells).
[0068] Five to seven days later, the cytopathic effect (CPE) of all wells was examined, and the TCID was calculated with or without the specified substance using the method of Reed et al. 50 dose.
[0069] Cell culture
[0070] African green monkey kidney epithelial cells (VeroE6, obtained from biomedica) were maintained in Gibco limited essential medium supplemented with Earle's salt and L-glutamine (Gibco 11095-080, 500 mL), 5% FCS, and 1% PenStrep (hereinafter referred to as MEM 5%). Unless otherwise specified, the cells were incubated at 37°C and 5% CO2.
[0071] Virus: Preparation of stock solution and titer determination
[0072] SARS-CoV-2 strain: Human 2019-nCoV isolate
[0073] Product Description Ref-SKU: 026V-03883, Human 2019-nCoV Infected Cell Culture Supernatant
[0074] Product Risk Grouping: RG3 ICTV
[0075] Classification: ssRNA(+) / Order Nidovirales / Family Coronaviridae / Genus Coronavirus / Beta Coronavirus
[0076] Virus name: Human 2019-nCoV strain: BavPat1 / 2020
[0077] Separate: Germany
[0078] Based on the stock solution of the 2.2 E+06 PFU / mL human 2019-nCoV isolate, the working viral stock solution (VPN3) was cultured in EMEM (Gibco) + 10% FCS. For the working stock solution, TCID... 50 Both titer and plaque assays were performed in duplicate, and the results showed a concentration of 1.30E+06 viral RNA copies per µL of stock solution. Aliquots were stored at -80°C. For infection assays, the working stock solution was thawed and diluted to an MOI of 0.002 in MEM 2%.
[0079] The European Commission classifies SARS-CoV-2 as a Level 3 risk pathogen. Experiments using live virus and high concentrations of viral stock solution must be conducted under Biosafety Level 3 (BSL-3) conditions. At the Institute of Pathology, Graz University of Medical Sciences, all work procedures using live virus are performed under BSL-3 conditions with enhanced personal safety equipment to prevent the virus from spreading via aerosols.
[0080] substance
[0081] The substances were dissolved in DMSO (Sigma) to prepare stock solutions of 5 mM or 1 mM. For some substances, a further 1:2 dilution was performed to obtain 2.5 mM and 0.5 mM stock solutions. The final experimental concentration was achieved by diluting the stock solution 1:100 in MEM2% per well. Stock solutions were freshly prepared before each assay.
[0082] Cytotoxicity assay
[0083] To perform cytotoxicity assays, VeroE6 cells were seeded into 96-well plates at 8,500 to 10,000 cells per well using MEM supplemented with 2% FCS 24 hours prior to material treatment. The plates were incubated at 37°C with 5% CO2.
[0084] After incubation, cells were exposed to a 1:100 diluted stock solution of the substance in MEM + 2% FCS (as described above). Each substance and concentration was tested three times. Immediately after substance addition, at 24 hours, and at 48 hours. Subsequently, metabolic activity was measured using an amaranth-based assay (resazurin). After adding amaranth (10 µM concentration), the increment of relative fluorescence units (RFU) was continuously measured for 3 hours, and linear regression analysis was performed. The slope of the substance-treated cells was normalized to the slope of the untreated cells (untreated cells = cells + corresponding amount of culture medium) to calculate relative metabolic activity.
[0085] Infection testing
[0086] Unless otherwise specified, prepare VeroE6 cells for infection assays 2.5 x 10⁶ per well (300 µL) 24 hours in advance. 4 Up to 3.0 x 10 4 Cells were seeded at a density of 1,000 cells in MEM + 2% FCS in 48-well plates (Corning Costar, cell culture medium treated).
[0087] On the day of infection, after removing the inoculation medium, cells were treated with MEM 2% FCS containing 1% DMSO + a substance dissolved to the specified concentration, to a final volume of 198 µL. Subsequently, 2 µL of diluted SARS-CoV-2 virus stock solution (calculated as MOI 0.002) was added. Cells were infected with the virus at 5% CO2 and 37°C for 1 hour. After the incubation step, the infection medium was removed, and cells were washed twice with MEM without FCS. 440 µL of fresh MEM 2% FCS (with or without the substance) was added to the cells. After 10 minutes, the supernatant (140 µL) at time point 0 was collected and stored at -80°C or inactivated with 560 µL AVL buffer.
[0088] Cells were incubated at 37°C with 5% CO2 for 48 hours, and the supernatant was harvested at time point 48 and inactivated with 560 µl of AVL buffer. Alternatively, cells could be lysed in wells for intracellular virus detection (using RTX buffer from the Qiagen RNeasy kit, followed by RNA preparation according to the kit's protocol), or the plates could be fixed in 4% formalin for SARS-specific immunohistochemical staining (IHC).
[0089] RNA isolation and RT-qPCR
[0090] Virus-containing supernatant samples were inactivated with AVL buffer (Qiagen), and viral RNA was isolated using the QiAmp Viral RNA Mini Kit (Qiagen) according to the manufacturer's recommended protocol by the CDC. RNA was eluted in 40 µL of ultrapure H2O and stored at -80 °C.
[0091] The RT-qPCR for detecting viral load in samples was performed according to CDC recommendations, using the QuantiTect multiplex RT-PCR kit and the Rotor Gene Q cycler:
[0092]
[0093] Rotorgene
[0094] qRT-PCR analysis was performed using Rotorgene and following the manufacturer's protocol.
[0095]
[0096] Immunohistochemistry
[0097] Cells were fixed with 4% formalin and washed with PBS, then permeated with PBS containing 0.1% Triton X 100 for 10 minutes (200 µl per well), followed by three washes with 200 µl PBS. Endogenous peroxidase was blocked with methanol solution containing 3% H2O2 for 30 minutes. Afterward, cells were washed three times with 200 µl PBS and incubated for 1 hour with 100 µl / well of primary antibody (SARS-CoV-2 nucleocapsid; diluted 1:1000 in antibody dilution buffer). Following this, cells were washed three times with 200 µl PBS, and in another incubation step, they were treated with secondary antibody (EnVision) for at least 30 minutes (protected from light).
[0098] After washing (PBS 3x), add 2 drops of substrate AEC to the cells and incubate until the virus-infected cells are stained red (observable under a microscope), but no later than 3 minutes. Stop the reaction by washing with PBS (3x). Store the wells in PBS until photographed for archiving.
[0099]
[0100] Molecular interaction assays were used to detect the inhibition of ACE2 receptor binding by RBD.
[0101] The molecular interaction assay for detecting the inhibitory effect of RBD on ACE2 receptor binding was performed as described in the literature (Gattinger et al., Allergy, 76 (2021), 878–883), with the following modifications: 200 ng of His-labeled RBD was incubated with different doses (100, 50, 25, 12.2, and 6 mM) of substance X at room temperature for 3 hours, followed by incubation on plates bound to ACE2 (2 μg / ml) for 3 hours. The bound RBD was then detected with mouse monoclonal anti-His antibody, followed by HRP-labeled anti-mouse IgG1 antibody, and finally by ABTS. All measurements were performed in duplicate, with a variation of <5%.
[0102] result
[0103] In the first set of experiments, TCID of SARS-CoV-2 was analyzed using Vero cells after pre-incubation with DMSO or a designated substance (IX) dissolved in DMSO. 50 As expected, DMSO reduced the TCID of SARS-CoV-2. 50 A 1 Log reduction was achieved. Cells were seeded, infected for 1 hour, and then different concentrations of the compound were added for 48 hours. All substances exhibited cytoprotective effects, with TCID50 reduced by at least 1 Log. 50The viral replication was significantly reduced by 50 µM of substance IV (99.7-fold and 802-fold reduction), VIII (99.7-fold and 5.14-fold reduction), and X (99.7-fold and 2107-fold reduction), indicating inhibition of viral replication (Table 1 and). Figure 2 ).
[0104] Table 1:
[0105]
[0106] In vitro inhibition of viral replication was replicated in another laboratory:
[0107] Vero cells were seeded into 48-well plates as described in the Methods section, then infected and incubated for 48 hours with all 10 compounds at different concentrations. Compounds IV, VIII, and X showed inhibitory effects on viral replication, consistent with the results of the first group of experiments (TCID). 50 The results observed were consistent with those observed in the assay. Then, qPCR for SARS-CoV-2 was performed in the supernatant after RNA isolation. Compound IV, at a concentration of 50 µM, resulted in a ct value exceeding 30 in one of the two replicates. A ct value exceeding 30 was also observed after incubation with 50 µM of compound VIII. Compound X, after treatment with 25 and 50 µM for 48 hours, resulted in an increase in ct value (above 30), demonstrating an inhibitory effect on viral replication (see also: Figure 3 , 4 and 5).
[0108] To determine whether the inhibition of viral replication was due to altered viral uptake of host cells, cells were further incubated for one hour with compounds IV, VIII, and X (compounds proven effective in previous experiments) while simultaneously being infected, after which the compounds were washed away. The cell supernatant was then tested by qPCR as described above. Interestingly, compared to the untreated control, compounds IV and VIII had no effect on viral replication, while compound X inhibited viral replication in a concentration-dependent manner after a short incubation of 1 hour. The results are as follows: Figure 7 As shown, after incubation at 25 or 50 µM for one hour, the ct value increased significantly.
[0109] This result indicates that viral uptake of host cells can be inhibited by compound X. Therefore, it was investigated whether compound X could block the ACE2 receptor, which is believed to be the entry point for viruses into cells.
[0110] The effects of compounds IV, VIII, and X on the ACE2 receptor were then tested. In this test, compounds IV and VIII did not show any inhibitory effect on ACE2 receptor binding. Compound X inhibited ACE2 binding in a concentration-dependent manner. At a concentration of 100 µM, it inhibited 21–31% of ACE2 binding (see [link to test results]). Figure 8 This indicates that compound X can inhibit viral uptake into cells at a very early stage, which is at least partly attributed to the compound's binding to the ACE2 receptor.
[0111] Comparison of trihydroxystilbene (resveratrol), tetrahydroxystilbene (haypericin), and hexahydroxystilbene (compound X of this invention) Example
[0112] The comparative tests of resveratrol, paclitaxel, and hexahydroxystilbene (compound X of the present invention) were performed as described above. Vero E6 cells were used as the cell system. Cells were infected with the virus for 1 hour, and then the test compounds were added. The cells were then washed and incubated with the test compounds for 48 hours. Results / readings were obtained by supernatant qPCR and IHC.
[0113] result
[0114] The results of these comparative tests can be found in... Figure 9 ~ 14. Hexahydroxystilbene completely inhibited viral replication (100 µM and 80 µM); trihydroxystilbene showed low inhibition of viral replication (100 µM, showing concentration dependence); tetrahydroxystilbene did not show any inhibitory effect on viral replication.
[0115] In view of this disclosure and its embodiments, the following preferred embodiments are disclosed in this specification:
[0116] 1. Compound of Formula I
[0117]
[0118] Wherein R1 to R6 are the same or different and are H, OH- or OR7, wherein R7 is a C1 to C3 alkyl or C1 to C4 acyl, provided that at least four of R1 to R6 are not H, the compound is used to treat and prevent COVID-19 in human subjects, particularly to inhibit SARS-CoV-2.
[0119] 2. The compound used according to embodiment 1, wherein the compound is selected from 3,5,4'-trimethoxystilbene, 3,3',5,5'-tetramethoxystilbene, 3,4,4',5-tetramethoxystilbene, 3,3',4,5'-tetramethoxystilbene, 3,3',4,5,5'-pentamethoxystilbene, 3,3',5,5'-tetrahydroxystilbene, 3,4,4',5-tetrahydroxystilbene, 3,3',4,4',5-tetrahydroxystilbene, 3,3',4,4',5-pentahydroxystilbene, 3,3',4,5,5'-pentahydroxystilbene, 3,4,4',5,5'-pentahydroxystilbene, 3, 3',4,4',5,5'-hexahydroxystilbene, preferably 3,3',4,5,5'-pentamethoxystilbene, 3,3',4,4',5-pentahydroxystilbene, 3,3',4,5,5'-pentahydroxystilbene, 3,4,4',5,5'-pentahydroxystilbene, 3,3',4,4',5,5'-pentahydroxystilbene, 3,3',4,4',5,5'-hexahydroxystilbene, especially 3,3',4,4',5,5'-hexahydroxystilbene.
[0120] 3. The compound used according to embodiment 1 or 2, wherein inhibition of SARS-CoV-2 is a cytopathic effect that inhibits the replication of SARS-CoV-2 and / or prevents active viral replication of SARS-CoV-2 and / or prevents SARS-CoV-2 viral infection via airborne transmission.
[0121] 4. A pharmaceutical preparation comprising, or consisting of, a compound according to any one of embodiments 1 to 3 as an active ingredient and a pharmaceutically acceptable excipient.
[0122] 5. The pharmaceutical formulation used according to embodiment 4, wherein the formulation is for oral, sublingual, intramuscular, subcutaneous, intranasal, oral mucosal, bronchial, pulmonary, skin, peritoneal or rectal administration, preferably for oral, sublingual or intranasal administration, and in particular the formulation is provided as an inhalable and / or aerosol composition, or as a nasal or oral spray, and / or as a sublingual film or tablet, and / or in lollipop form.
[0123] 6. The pharmaceutical formulation used according to embodiment 4 or 5, wherein the pharmaceutically acceptable excipient is selected from diluents, such as water, acetone, ethanol, polyethylene glycol, polypropylene glycol, 1,3-propanediol, 1,3-butanediol, isopropyl myristate, isopropyl palmitate, mineral oil, ethoxylated isostearyl alcohol, polyoxyethylene isostearyl alcohol, polyoxyethylene sorbitan fatty acid ester; carriers, such as glycerol, mannitol, sorbitol, xylitol, and erythritol; absorbents, such as starch, dextrin, calcium sulfate, lactose, mannitol, sucrose, sodium chloride, glucose, urea, kaolin, microcrystalline cellulose, aluminum silicate; wetting agents and binders, such as water, glycerol, polyethylene glycol, ethanol, propanol, starch syrup, dextrin, syrup, honey, glucose solution, gum arabic syrup, gelatin syrup, sodium carboxymethyl cellulose, shellac, methylcellulose, potassium phosphate, polyethylene. Pyrrolidone; disintegrants, such as dry starch, alginate, agar powder, sodium bicarbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid ester, sodium dodecyl sulfate, methylcellulose, ethylcellulose; disintegration inhibitors, such as sucrose, tristearate, cocoa butter, hydrogenated oil; absorption enhancers, such as quaternary ammonium salts, sodium dodecyl sulfate; lubricants, such as talc, silica, corn starch, stearic acid, boric acid, liquid paraffin, polyethylene glycol; polyacrylic acid resins, liposomes, water-soluble carriers such as PEG4000 and PEG6000, PVP; antioxidants; pH buffers and / or salt buffers; solubility regulators; penetration enhancers; antioxidants, such as citric acid and its salts, tartaric acid and its salts, phosphoric acid and its salts, and ethylenediaminetetraacetic acid (EDTA) and its salts, vitamins C and E; or mixtures thereof.
[0124] 7. The pharmaceutical formulation used according to any one of embodiments 4 to 6, wherein the formulation is an inhaler or aerosol formulation, particularly an isotonic inhalation solution or suspension or a liquid or powder aerosol.
[0125] 8. The pharmaceutical preparation used according to any one of embodiments 4 to 7, wherein the content of the compound in the preparation is from about 100 μg to about 10 g, preferably from about 1 mg to about 1 g, more preferably from about 10 mg to 500 mg, and even more preferably from about 20 mg to about 300 mg.
[0126] 9. The pharmaceutical preparation used according to any one of embodiments 4 to 8, wherein the content of the compound in the preparation is from about 10 mg to about 1000 mg, preferably from about 25 mg to about 750 mg, more preferably from 50 mg to 500 mg, and even more preferably from about 30 mg to about 100 mg.
[0127] 10. A pharmaceutical formulation used according to any one of embodiments 4 to 9, wherein the formulation is contained in a metered inhaler, a dry powder inhaler, or a nebulizer.
[0128] 11. A pharmaceutical formulation used according to any one of embodiments 4 to 9, wherein the formulation comprises 0.001% to 50% w / v, preferably 0.01% to 20% w / v, more preferably 0.1% w / v to 20% w / v, and particularly 1% to 20% w / v of the compound.
[0129] 12. Use of the compounds according to embodiments 1 to 3 in the preparation of a pharmaceutical formulation according to any one of embodiments 4 to 11, said pharmaceutical formulation for the treatment and prevention of COVID-19 in human subjects, particularly for the inhibition of SARS-CoV-2.
[0130] 13. The purpose according to implementation scheme 12 is to inhibit the replication of SARS-CoV-2, and / or to prevent the cytopathic effect of active viral replication of SARS-CoV-2, and / or to prevent SARS-CoV-2 viral infection via airborne transmission.
[0131] 14. A method for treating and preventing COVID-19, particularly inhibiting SARS-CoV-2, in human subjects, wherein an effective amount of a compound according to embodiments 1 to 3 or a pharmaceutical preparation according to any one of embodiments 4 to 11 is administered to a subject who has been infected with SARS-CoV-2 or is at risk of being infected with SARS-CoV-2.
[0132] 15. A method for inhibiting SARS-CoV-2 replication and / or preventing cytopathic effects of active SARS-CoV-2 viral replication and / or preventing SARS-CoV-2 viral infection via airborne transmission in human subjects, wherein an effective amount of the compound according to embodiments 1 to 3 or the pharmaceutical preparation according to any one of embodiments 4 to 11 is administered to a subject who is infected with SARS-CoV-2 or at risk of being infected with SARS-CoV-2.
[0133] 1. A compound selected from (-)-epigallocatechin gallate, (-)-gallocatechin gallate, or mixtures thereof, preferably (-)-gallocatechin gallate or mixtures thereof, for the treatment and prevention of COVID-19 in human subjects, particularly for the inhibition of SARS-CoV-2.
[0134] 2. The compound used according to embodiment 1, wherein the compound is (-)-gallocatechin gallate (“Substance No. VIII”).
[0135] 3. The compound used according to embodiment 1 or 2, wherein inhibiting SARS-CoV-2 is an inhibitory effect on the replication of SARS-CoV-2 and / or a cytopathic effect on the active viral replication of SARS-CoV-2 and / or a preventive effect on SARS-CoV-2 infection via airborne transmission.
[0136] 4. A pharmaceutical preparation comprising, or consisting of, a compound according to any one of embodiments 1 to 3 as an active ingredient and a pharmaceutically acceptable excipient.
[0137] 5. The pharmaceutical formulation used according to embodiment 4, wherein the formulation is for oral, sublingual, intramuscular, subcutaneous, nasal, oral mucosal, bronchial, lung, skin, peritoneal or rectal administration, preferably for oral, sublingual or nasal administration, and in particular the formulation is provided as an inhalable and / or aerosol composition or as a nasal or oral spray and / or as a sublingual film or tablet and / or as a lollipop.
[0138] 6. The pharmaceutical formulation used according to embodiment 4 or 5, wherein the pharmaceutically acceptable excipient is selected from diluents, such as water, acetone, ethanol, polyethylene glycol, polypropylene glycol, 1,3-propanediol, 1,3-butanediol, isopropyl myristate, isopropyl palmitate, mineral oil, ethoxylated isostearyl alcohol, polyoxyethylene isostearyl alcohol, polyoxyethylene sorbitan fatty acid ester; carriers, such as glycerol, mannitol, sorbitol, xylitol, and erythritol; absorbents, such as starch, dextrin, calcium sulfate, lactose, mannitol, sucrose, sodium chloride, glucose, urea, kaolin, microcrystalline cellulose, aluminum silicate; wetting agents and binders, such as water, glycerol, polyethylene glycol, ethanol, propanol, starch syrup, dextrin, syrup, honey, glucose solution, gum arabic syrup, gelatin syrup, sodium carboxymethyl cellulose, shellac, methylcellulose, potassium phosphate, polyethylene. Pyrrolidone; disintegrants, such as dry starch, alginate, agar powder, sodium bicarbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid ester, sodium dodecyl sulfate, methylcellulose, ethylcellulose; disintegration inhibitors, such as sucrose, tristearate, cocoa butter, hydrogenated oil; absorption enhancers, such as quaternary ammonium salts, sodium dodecyl sulfate; lubricants, such as talc, silica, corn starch, stearic acid, boric acid, liquid paraffin, polyethylene glycol; polyacrylic acid resins, liposomes, water-soluble carriers such as PEG4000 and PEG6000, PVP; antioxidants; pH buffers and / or salt buffers; solubility regulators; penetration enhancers; antioxidants, such as citric acid and its salts, tartaric acid and its salts, phosphoric acid and its salts, and ethylenediaminetetraacetic acid (EDTA) and its salts, vitamins C and E; or mixtures thereof.
[0139] 7. The pharmaceutical formulation used according to any one of embodiments 4 to 6, wherein the formulation is an inhalation or aerosol formulation, particularly an isotonic inhalation solution or suspension or a liquid or powder aerosol.
[0140] 8. A pharmaceutical preparation used according to any one of embodiments 4 to 7, wherein the preparation contains about 100 μg to about 10 g, preferably about 1 mg to about 1 g, more preferably 10 mg to 500 mg, and even more preferably about 20 mg to about 300 mg of a compound.
[0141] 9. A pharmaceutical preparation used according to any one of embodiments 4 to 8, wherein the preparation contains a compound in an amount of about 10 mg to about 1000 mg, preferably about 25 mg to about 750 mg, more preferably 50 mg to 500 mg, and even more preferably about 30 mg to about 100 mg.
[0142] 10. A pharmaceutical formulation used according to any one of embodiments 4 to 9, wherein the formulation is contained in a metered inhaler, a dry powder inhaler, or a nebulizer.
[0143] 11. A pharmaceutical formulation used according to any one of embodiments 4 to 9, wherein the formulation contains 0.001% to 50% w / v, preferably 0.01% to 20% w / v, more preferably 0.1% to 20% w / v, and particularly 1% to 20% w / v of a compound.
[0144] 12. Use of a compound according to any one of embodiments 1 to 3 in the preparation of a pharmaceutical formulation according to any one of embodiments 4 to 11, said pharmaceutical formulation being used to treat and prevent COVID-19 in human subjects, particularly for inhibiting SARS-CoV-2.
[0145] 13. As per the use of embodiment 12, for inhibiting the replication of SARS-CoV-2 and / or for preventing the cytopathic effect of active viral replication of SARS-CoV-2 and / or for preventing SARS-CoV-2 viral infection via airborne transmission.
[0146] 14. A method for treating and preventing COVID-19, particularly inhibiting SARS-CoV-2, in human subjects, wherein an effective amount of a compound according to any one of embodiments 1 to 3 or a pharmaceutical preparation according to any one of embodiments 4 to 11 is administered to a subject who is infected with SARS-CoV-2 or at risk of being infected with SARS-CoV-2.
[0147] 15. A method for inhibiting SARS-CoV-2 replication and / or preventing cytopathic effects of active SARS-CoV-2 viral replication and / or preventing SARS-CoV-2 infection via airborne transmission in human subjects, wherein an effective amount of a compound according to any one of embodiments 1 to 3 or a pharmaceutical preparation according to any one of embodiments 4 to 11 is administered to a subject who is infected with SARS-CoV-2 or at risk of being infected with SARS-CoV-2. sequence list <110> Thomas Szekeres Walter Jager <120> Compounds used to treat and prevent COVID-19 <130> R79372 <150> EP21164852 <151> 2021-03-25 <150> EP21164854 <151> 2021-03-25 <160> 3 <170> PatentIn version 3.5 <210> 1 <211> 20 <212> DNA <213> SARS-CoV-2 <400> 1 Gaccccaaaa tcagcgaaat 20 <210> 2 <211> twenty four <212> DNA <213> SARS-CoV-2 <400> 2 tctggttact gccagttgaa tctg 24 <210> 3 <211> twenty four <212> DNA <213> SARS-CoV-2 <400> 3 accccgcatt acgtttggtg gacc 24
Claims
1. 3,3',4,4',5,5'-Hexahydroxytrans-stilbene in the preparation of pharmaceutical formulations for the treatment and prevention of COVID-19 in human subjects.
2. The use according to claim 1, wherein the pharmaceutical preparation comprises 3,3',4,4',5,5'-hexahydroxytrans-stilbene as an active ingredient and comprises, or is composed of, a pharmaceutically acceptable excipient.
3. The use according to claim 1, wherein the formulation is for oral, intramuscular, subcutaneous, intranasal, oral mucosal, pulmonary, skin, peritoneal or rectal administration.
4. The use according to claim 1, wherein the formulation is for oral, sublingual, bronchial or intranasal administration.
5. The use according to claim 1, wherein the formulation is provided as an inhalable composition, or as a nasal or oral spray, and / or as a sublingual film or tablet, and / or in lollipop form.
6. The use according to claim 5, wherein the inhalable composition is an aerosol composition.
7. The use according to claim 2, wherein the pharmaceutically acceptable excipient is selected from diluents; carriers; absorbents; wetting agents and binders; disintegrants; disintegration inhibitors; absorption promoters; lubricants; polyacrylic resins, liposomes, antioxidants; pH buffers and / or salt buffers; solubility regulators; penetration promoters; antioxidants; or mixtures thereof.
8. The use according to claim 7, wherein the diluent is selected from water, acetone, ethanol, polyethylene glycol, polypropylene glycol, 1,3-propanediol, 1,3-butanediol, isopropyl myristate, isopropyl palmitate, mineral oil, ethoxylated isostearyl alcohol, polyoxyethylene isostearyl alcohol, and polyoxyethylene sorbitan fatty acid ester; the carrier is selected from glycerol, mannitol, sorbitol, xylitol, and erythritol; the absorbent is selected from starch, dextrin, calcium sulfate, lactose, mannitol, sucrose, sodium chloride, glucose, urea, kaolin, microcrystalline cellulose, and aluminum silicate; and the wetting agent and binder are selected from water, glycerol, polyethylene glycol, ethanol, propanol, starch syrup, dextrin, syrup, honey, glucose solution, and gum arabic. Syrups, gelatin syrup, sodium carboxymethyl cellulose, shellac, methylcellulose, potassium phosphate, polyvinylpyrrolidone; disintegrants selected from dry starch, alginate, agar powder, sodium alginate, sodium bicarbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid ester, sodium dodecyl sulfonate, methylcellulose, ethylcellulose; disintegration inhibitors selected from sucrose, tristearate, cocoa butter, hydrogenated oil; absorption promoters selected from quaternary ammonium salts, sodium dodecyl sulfate; lubricants selected from talc, silica, corn starch, stearic acid, boric acid, liquid paraffin, polyethylene glycol; or antioxidants selected from citric acid and its salts, tartaric acid and its salts, phosphoric acid and its salts, ethylenediaminetetraacetic acid and its salts, vitamins C and E.
9. The use according to claim 2, wherein the pharmaceutically acceptable excipient is a water-soluble carrier.
10. The use according to claim 9, wherein the water-soluble carrier is selected from PEG4000 and PEG6000, PVP.
11. The use according to claim 1, wherein the formulation is an inhalant.
12. The use according to claim 11, wherein the inhalant is an aerosol.
13. The use according to claim 11, wherein the inhalant is an isotonic inhalation solution or suspension.
14. The use according to claim 12, wherein the aerosol is a liquid or powder aerosol.
15. According to claim 1, the preparation contains 100 μg to 10 g of 3,3',4,4',5,5'-hexahydroxytrans-stilbene.
16. The use according to claim 1, wherein the content of 3,3',4,4',5,5'-hexahydroxytrans-stilbene in the preparation is from 1 mg to 1 g.
17. The use according to claim 1, wherein the content of 3,3',4,4',5,5'-hexahydroxytrans-stilbene in the preparation is from 10 mg to 500 mg.
18. The use according to claim 1, wherein the content of 3,3',4,4',5,5'-hexahydroxytrans-stilbene in the preparation is from 20 mg to 300 mg.
19. The preparation according to claim 1, wherein the content of 3,3',4,4',5,5'-hexahydroxytrans-stilbene in the preparation is from 10 mg to 1000 mg.
20. The preparation according to claim 1, wherein the content of 3,3',4,4',5,5'-hexahydroxytrans-stilbene is from 25 mg to 750 mg.
21. According to claim 1, the preparation contains 50 mg to 500 mg of 3,3',4,4',5,5'-hexahydroxytrans-stilbene.
22. According to claim 1, the preparation contains 3,3',4,4',5,5'-hexahydroxytrans-stilbene in a concentration of 30 mg to 100 mg.
23. The use according to claim 1, wherein the formulation is contained in a metered inhaler, a dry powder inhaler, or a nebulizer.
24. The use according to claim 1, wherein the formulation comprises 0.001% to 50% w / v of 3,3',4,4',5,5'-hexahydroxytrans-stilbene.
25. The use according to claim 1, wherein the formulation comprises 0.01% to 20% w / v of 3,3',4,4',5,5'-hexahydroxytrans-stilbene.
26. The use according to claim 1, wherein the formulation comprises 0.1% w / v to 20% w / v of 3,3',4,4',5,5'-hexahydroxytrans-stilbene.
27. The use according to claim 1, wherein the formulation comprises 1% to 20% w / v of 3,3',4,4',5,5'-hexahydroxytrans-stilbene.
Citation Information
Patent Citations
Extract of Rheum lhasaense A.J.Li etP.K.Hsiao and application of extract of Rheum lhasaense A.J.Li etP.K.Hsiaoin in preparation of medicine for preventing and / or treating viral pneumonia
CN111228343A
Polyhydroxy stilbenes compound preparation and uses as drugs for suppressing SARS
CN1736986A
Substituted stilbenes, their reactions and anticancer activity
WO2002050007A2
Novel 1,2-diphenylethene derivatives for treatment of immune diseases
WO2002057219A1
Stilbene derivatives and their use in medicaments
WO2005016860A2
